Data Science Award – HT942526PCRPDSA
- Letters of Intent due 12 August 2026
- Up to USD$1.4M over 3 years
- Supports research that develops or uses quantitative and analytical approaches, processes, and/or systems to obtain knowledge and insight from large and/or complex sets of prostate cancer data in one or more of the following research areas:
- Analysis of clinically annotated datasets
- Analysis of “-omics” data
- Artificial intelligence and machine learning
- Bioinformatics
- Computational biology
- Digital pathology
- Epidemiology
- Medical imaging
- retrospective clinical research allowed, but not required
- prospective recruitment of human subjects and clinical trials not allowed
- preliminary data encouraged but not required
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526PCRPDSA_GG
Early Investigator Research Award –HT942526PCRPEIRA
- Letters of Intent due 12 August 2026
- Up to USD$630,000 over 3 years
- Supports prostate cancer research conducted by investigators in the early stages of their careers with guidance from an experienced prostate cancer researcher mentor.
- investigators with fewer than 3 years postdoctoral research experience, excluding clinical residency or clinical fellowship training
- must include an experienced prostate cancer researcher as mentor
- must include a researcher development plan
- clinical research allowed
- clinical trials not allowed
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526PCRPEIRA_GG
Idea Development Award – HT942526PCRPIDA
- Letters of Intent due 12 August 2026
- Up to USD$1.7M over 3 years (Established Investigator Option) or up to USD$2.1M over 4 years (New Investigator Option)
- New Investigators – at least 3 years postdoctoral training/fellowship or within 10 years of terminal degree completion; not previously received a PCRP Idea Development and/or Health Disparity Research Award
- Supports new ideas that represent innovative, high-risk and high-gain approaches to prostate cancer research.
- Emphasizes innovation and impact equally.
- preliminary data encouraged, but not required
- multi-disciplinary projects encouraged
- multi-institutional projects allowed
- correlative studies associated with an ongoing or completed clinical trial allowed
- clinical trials not allowed
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526PCRPEIRA_GG
Physician Research Award – HT942526PCRPPRA
- Letters of Intent due 12 August 2026
- Up to USD$1.1M over 4 years
- early-career clinician investigators in the last year of an accredited medical residency or fellowship program; or within 5 years of initiating a faculty appointment
- Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.
- PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.
- must include a researcher development plan
- clinical trials not allowed
- Must address at least one of the overarching challenges
- Apply here
- Document – Program Announcement – HT942526PCRPPRA_GG
Overarching Challenges
- Improve overall health, wellness and survivorship for those impacted by prostate cancer
- Develop new treatments or improve existing therapies to improve outcomes for patients with lethal prostate cancer
- Enhance clinical care for all patients with prostate cancer
- Define the biology of prostate cancer progression to lethal prostate cancer to reduce death
